The Proteus management team is comprised of experienced business and technical leaders who are pushing the limits of current research. Our researchers have a diverse mix of skills across computational chemistry, molecular modeling and experimental science. The core members include the following individuals.
Karl Ruping is founder and CEO of Proteus. He is an experienced biotechnology entrepreneur and patent attorney with a technical background in computational sciences and bioinformatics. He is a founder of Agrivida (agricultural biotechnology) MolySym, (molecular simulation) and incTANK Ventures (early stage venture capital fund). Karl studied economics at Colby College and computer science at Temple University, received a Juris Doctorate from Boston University, and was a Research Fellow at MIT’s School of Engineering.
Justin Boyd is co-founder and consultant for Proteus where he oversees the company’s research efforts and scientific partnerships. He is a Research Investigator in the Laboratory of Drug Discovery in Neurodegeneration with the Harvard NeuroDiscovery Center and Department of Neurology at the Brigham & Women’s Hospital. Justin has fifteen years of research experience in neuroscience, stem cell research and drug discovery. He is published in the fields of neurobiology, stem cell biology, infectious diseases and drug discovery, reflecting his strong experience in interdisciplinary approaches to research. As a domain expert in high content analysis, Justin is active in developing disruptive analytical tools for phenotypic drug discovery at Proteus.
Marius Vilkas is Senior Software Engineer for Proteus where he develops new systems and solutions for our diverse drug discovery and design infrastructure. Before Proteus, he was lead engineer at MolySym where he develop a full-body molecular modeling and molecule-molecule docking system. Prior to that, he managed projects on protein-ligand and cell membrane dynamics at the University of Kentucky College of Pharmacy and supervised atomic-level particle simulation research at the University of Puerto Rico’s Theoretic Chemical Physics Laboratory and the High Performance Computing Facility.
Proteus actively engages a network of academic and industry collaborators from across leading universities, teaching hospitals and research labs. As part of our extended team of specialists, these collaborators bring unique skills new insights from the forefront of medical innovations. Our extended team includes:
Marcie Glicksman, PhD
Dr. Marcie Glicksman brings to the Proteus team extensive experience in assay development, high throughput screening, and chemical databases, as well as animal pharmacology and preclinical development. She is the Co-Director of the Laboratory for Drug Discovery in Neurodegeneration (LDDN) which is part of the Harvard NeuroDiscovery Center. She is also assistant professor in the Neurology Department at Brigham and Women’s Hospital and Harvard Medical School, while also serving on the science advisory board for the Alzheimer’s Drug Discovery Foundation of the Institute for the Study of Aging (ADDF/ISOA).
Gregory Cuny, PhD
Dr. Greg Cuny is an experienced medicinal chemist, providing Proteus with the skills needed to design a new class of brain-penetrant kinase inhibitors. Previously a colleague with Dr. Ray and Dr. Glicksman at the Laboratory for Drug Discovery in Neurodegeneration in Harvard’s NeuroDiscovery Center, he is now Assistant Professor of Medicinal Chemistry at the University of Houston’s Department of Pharmacological and Pharmaceutical Sciences.
Proteus has formed select key strategic alliances with a number of partners that share our vision. These partnerships leverage new insights into genetically linked diseases to deliver breakthrough treatments to patients with neurodegenerative diseases, cancer, inflammatory/immunologic disorders and other diseases.
If you would like more information about partnering opportunities, please contact us.